Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay

Journal of Medical Virology

Volumn 79, Issue 8, 2007, Pages 1113-1119

  Kinai, Ei ^a   Hanabusa, Hideji ^b   Kato, Shingo ^c  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

^b Ogikubo Hospital   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Accurate prediction; Hepatitis C virus; Residual HCV RNA; Ultrasensitive RT PCR

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MALE; PREDICTION; QUANTITATIVE ANALYSIS; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS DETECTION;

ADULT; AGED; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PHENYLETHYL ALCOHOL; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 34347354194     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20908     Document Type: Article

References (22)

1. Cohen J. 1999. The scientific challenge of hepatitis C virus. Science 285:26-30.
2. Davis GL, Wong JB, McHutchinson JG, Manns MP, Harvey J, Albrecht J. 2003. Early Virologic response to treatment with peginterferon alfa-2b plus ribavirin in patinets with chronic Hepatitis C. Hepatology 38:645-652.
3. Desombere I, Vlierberghe HV, Couvent S, Clinckspoor F, Leroux-Roels G. 2005. Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Qualification: Impact on Diagnosis and Treatment of HCV Infections. J Clin Microbiol 43:2590-2597.
4. European Association for the Study of the Liver. 1999. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, consensus statement. J Hepatol 30:956-961.
5. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
6. Gerotto M, Pero FD, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, Fagiuoli S, realdon S, Alberti A. 2006. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 40:83-87.
7. Gorrin G, Friesenhahn M, Lin P, Sanders M, Pollner R, Eguchi B, Pham J, Roma G, Spidle J, Nicl S, Wong C, Bhade S, Comanor L. 2003. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription mediated amplification. J Clin Microbiol 41:310-317.
8. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, for the PEGASYS International Study Group. 2004. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
9. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy R, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. 2006. Early Identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43:954-960.
10. Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, Rakela J. 2000. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 181:442-448.
11. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiftman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, International Hepatitis Interventional Therapy Group. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958-965.
12. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiftman-ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, the HALT-C Trial Group. 2006. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis. Hepatology 44:360-367.
13. National Institutes of Health Consensus Development Conference. 2002. Statement: Management of hepatitis C. Hepatology 36:S3-S20.
14. Puig M, Mihalik K, Yu MW, Feinstone SM, Major ME. 2002. Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay. J Virol Method 105:253-263.
15. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, KUbicka J, Wilkinson J, Adair D, Rakela J, Laskus T. 2005. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005. 41:106-114.
16. Saldanha J, Lelie N, Heath A, the WHO Collaborative Study Group. 1999. Establishment of the first international standard for nucleic acid amplification technoloby (NAT) assays for HCV RNA. Vox Sang 76:149-158.
17. Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. 2001. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatits C virus treated with peginterferon α-2a. J Clin Microbiol 39:2850-2855.
18. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Leigh Brown AJ. 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 64:864-872.
19. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
20. Torriani FJ, Todriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, for the APRICOT Study Group. 2004. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-infected Patients. N Eng J Med 351:438-450.
21. Watkins-Riedel T, Ferenci P, Steidl-Munda P, Gschwantler M, Mueller C, Woegerbauer M. 2004. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis. Clin Infect Dis 39:1754-1760.
22. Young KKY, Resnick RM, Myers TW. 1993. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 31:882-886.